FDA Grants Fast Track to Nuvation Bio's Safusidenib for IDH1-Mutant Glioma
NUVB has more than doubled off its 52-week low of $2.57.
Summary
The FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma, a regulatory milestone that could expedite development and review. This follows the Phase 2 J201 data showing a 51.9% confirmed objective response rate and 79.1% 36-month progression-free survival, with the pivotal Phase 3 SIGMA study already enrolling. The designation adds momentum to the pipeline and may shorten the path to market, though it does not guarantee approval. Nuvation Bio recently completed a $250 million convertible note offering, providing capital to advance these programs.
At the time of this announcement, NUVB was trading at $7.23 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $2.57 to $9.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.